These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

508 related articles for article (PubMed ID: 28467795)

  • 1. Survival benefit of glioblastoma patients after FDA approval of temozolomide concomitant with radiation and bevacizumab: A population-based study.
    Zhu P; Du XL; Lu G; Zhu JJ
    Oncotarget; 2017 Jul; 8(27):44015-44031. PubMed ID: 28467795
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dexamethasone administration during definitive radiation and temozolomide renders a poor prognosis in a retrospective analysis of newly diagnosed glioblastoma patients.
    Shields LB; Shelton BJ; Shearer AJ; Chen L; Sun DA; Parsons S; Bourne TD; LaRocca R; Spalding AC
    Radiat Oncol; 2015 Oct; 10():222. PubMed ID: 26520780
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypofractionated-intensity modulated radiotherapy (hypo-IMRT) and temozolomide (TMZ) with or without bevacizumab (BEV) for newly diagnosed glioblastoma multiforme (GBM): a comparison of two prospective phase II trials.
    Carlson JA; Reddy K; Gaspar LE; Ney D; Kavanagh BD; Damek D; Lillehei K; Chen C
    J Neurooncol; 2015 Jun; 123(2):251-7. PubMed ID: 25920710
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Survival benefits of hypofractionated radiotherapy combined with temozolomide or temozolomide plus bevacizumab in elderly patients with glioblastoma aged ≥ 75 years.
    Ohno M; Miyakita Y; Takahashi M; Igaki H; Matsushita Y; Ichimura K; Narita Y
    Radiat Oncol; 2019 Nov; 14(1):200. PubMed ID: 31718669
    [TBL] [Abstract][Full Text] [Related]  

  • 5. First-line bevacizumab contributes to survival improvement in glioblastoma patients complementary to temozolomide.
    Hata N; Mizoguchi M; Kuga D; Hatae R; Akagi Y; Sangatsuda Y; Amemiya T; Michiwaki Y; Fujioka Y; Takigawa K; Suzuki SO; Yoshitake T; Togao O; Hiwatashi A; Yoshimoto K; Iihara K
    J Neurooncol; 2020 Feb; 146(3):451-458. PubMed ID: 32020475
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neoadjuvant bevacizumab and irinotecan versus bevacizumab and temozolomide followed by concomitant chemoradiotherapy in newly diagnosed glioblastoma multiforme: A randomized phase II study.
    Hofland KF; Hansen S; Sorensen M; Engelholm S; Schultz HP; Muhic A; Grunnet K; Ask A; Costa JC; Kristiansen C; Thomsen C; Poulsen HS; Lassen U
    Acta Oncol; 2014 Jul; 53(7):939-44. PubMed ID: 24456504
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of temozolomide treatment used at the same time with radiotherapy and adjuvant temozolomide; concomitant therapy of glioblastoma multiforme: multivariate analysis and other prognostic factors.
    Birol Sarica F; Tufan K; Cekinmez M; Sen O; Cem Onal H; Mertsoylu H; Topkan E; Pehlivan B; Erdogan B; Nur Altinors M
    J Neurosurg Sci; 2010 Mar; 54(1):7-19. PubMed ID: 20436394
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Concurrent bevacizumab and temozolomide alter the patterns of failure in radiation treatment of glioblastoma multiforme.
    Shields LB; Kadner R; Vitaz TW; Spalding AC
    Radiat Oncol; 2013 Apr; 8():101. PubMed ID: 23618500
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Postoperative neoadjuvant temozolomide before radiotherapy versus standard radiotherapy in patients 60 years or younger with anaplastic astrocytoma or glioblastoma: a randomized trial.
    Malmström A; Poulsen HS; Grønberg BH; Stragliotto G; Hansen S; Asklund T; Holmlund B; Łysiak M; Dowsett J; Kristensen BW; Söderkvist P; Rosell J; Henriksson R;
    Acta Oncol; 2017 Dec; 56(12):1776-1785. PubMed ID: 28675067
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Toxicity and survival in primary glioblastoma patients treated with concomitant plus adjuvant temozolomide versus adjuvant temozolomide: results of a single-institution, retrospective, matched-pair analysis.
    Gutenberg A; Bock HC; Reifenberger G; Brück W; Giese A
    Acta Neurochir (Wien); 2013 Mar; 155(3):429-35. PubMed ID: 23254891
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Time trends in glioblastoma multiforme survival: the role of temozolomide.
    Dubrow R; Darefsky AS; Jacobs DI; Park LS; Rose MG; Laurans MS; King JT
    Neuro Oncol; 2013 Dec; 15(12):1750-61. PubMed ID: 24046259
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Standard (60 Gy) or short-course (40 Gy) irradiation plus concomitant and adjuvant temozolomide for elderly patients with glioblastoma: a propensity-matched analysis.
    Minniti G; Scaringi C; Lanzetta G; Terrenato I; Esposito V; Arcella A; Pace A; Giangaspero F; Bozzao A; Enrici RM
    Int J Radiat Oncol Biol Phys; 2015 Jan; 91(1):109-15. PubMed ID: 25442339
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Concurrent Chemoradiotherapy with Temozolomide Followed by Adjuvant Temozolomide for Newly Diagnosed Glioblastoma Patients: A Retrospective Multicenter Observation Study in Korea.
    Kim BS; Seol HJ; Nam DH; Park CK; Kim IH; Kim TM; Kim JH; Cho YH; Yoon SM; Chang JH; Kang SG; Kim EH; Suh CO; Jung TY; Lee KH; Kim CY; Kim IA; Hong CK; Yoo H; Kim JH; Kang SH; Kang MK; Kim EY; Kim SH; Chung DS; Hwang SC; Song JH; Cho SJ; Lee SI; Lee YS; Ahn KJ; Kim SH; Lim DH; Gwak HS; Lee SH; Hong YK
    Cancer Res Treat; 2017 Jan; 49(1):193-203. PubMed ID: 27384161
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A population-based study on the effect of temozolomide in the treatment of glioblastoma multiforme.
    Rønning PA; Helseth E; Meling TR; Johannesen TB
    Neuro Oncol; 2012 Sep; 14(9):1178-84. PubMed ID: 22869622
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I/IIa trial of fractionated radiotherapy, temozolomide, and autologous formalin-fixed tumor vaccine for newly diagnosed glioblastoma.
    Ishikawa E; Muragaki Y; Yamamoto T; Maruyama T; Tsuboi K; Ikuta S; Hashimoto K; Uemae Y; Ishihara T; Matsuda M; Matsutani M; Karasawa K; Nakazato Y; Abe T; Ohno T; Matsumura A
    J Neurosurg; 2014 Sep; 121(3):543-53. PubMed ID: 24995786
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glioblastoma in the elderly: the effect of aggressive and modern therapies on survival.
    Babu R; Komisarow JM; Agarwal VJ; Rahimpour S; Iyer A; Britt D; Karikari IO; Grossi PM; Thomas S; Friedman AH; Adamson C
    J Neurosurg; 2016 Apr; 124(4):998-1007. PubMed ID: 26452121
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glioblastoma Treatment with Temozolomide and Bevacizumab and Overall Survival in a Rural Tertiary Healthcare Practice.
    Carter TC; Medina-Flores R; Lawler BE
    Biomed Res Int; 2018; 2018():6204676. PubMed ID: 30687753
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Conditional probability of survival and post-progression survival in patients with glioblastoma in the temozolomide treatment era.
    McNamara MG; Lwin Z; Jiang H; Chung C; Millar BA; Sahgal A; Laperriere N; Mason WP
    J Neurooncol; 2014 Mar; 117(1):153-60. PubMed ID: 24469855
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized phase II trial of irinotecan and bevacizumab as neo-adjuvant and adjuvant to temozolomide-based chemoradiation compared with temozolomide-chemoradiation for unresectable glioblastoma: final results of the TEMAVIR study from ANOCEF†.
    Chauffert B; Feuvret L; Bonnetain F; Taillandier L; Frappaz D; Taillia H; Schott R; Honnorat J; Fabbro M; Tennevet I; Ghiringhelli F; Guillamo JS; Durando X; Castera D; Frenay M; Campello C; Dalban C; Skrzypski J; Chinot O
    Ann Oncol; 2014 Jul; 25(7):1442-1447. PubMed ID: 24723487
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Temozolomide during radiotherapy of glioblastoma multiforme : Daily administration improves survival.
    Nachbichler SB; Schupp G; Ballhausen H; Niyazi M; Belka C
    Strahlenther Onkol; 2017 Nov; 193(11):890-896. PubMed ID: 28197654
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.